Skip to main content
. 2012 Feb 29;2012:372518. doi: 10.1155/2012/372518

Table 2.

Clinical outcome of patients attending CAMEF during the in vivo study, 2007-2008 after treatment with Malartin and SP.

Parameter Clinical outcome
ACPR 92.53% (161)
ETF 0.60% (01)
LCF 03.45% (06)
LPF 03.45% (06)
Clinical treatment failure 07.50% (13)